Oscillo Biosciences is a neurotechnology company developing medical devices and digital therapeutic platforms to treat serious neurodegenerative diseases like Alzheimer's Disease, Parkinson's, aphasia, and dyslexia.Currently more than 23 million Americans and 55 million adults worldwide suffer from Alzheimers and dementia rising at an alarming rate of 10 million annually. Alzheimer’s disease is the 5th leading cause of death among Americans age 65 and older. Among the top 10 causes of death, it is the only one for which there is no known cure. Alzheimer's disease requires extensive medical care, including diagnosis, treatment, and ongoing management. The cost of healthcare services for Alzheimer's patients is substantial, straining healthcare systems in large countries. For instance, the estimated annual cost of Alzheimer's disease in the United States in 2022 was $321 billion. This cost is expected to increase to more than $1 trillion by 2050 making it the most expensive disease in the United States This cost includes Medicare and Medicaid expenses, hospital visits, and prescription medications. Our approach is predicated on the understanding that brain rhythms supporting memory and cognition are disrupted in people with Alzheimer’s disease. Oscillo Biosciences has developed a non-invasive medical device and accompanying digital therapeutic platform that works by synchronizing specialized light pulses with familiar music to rhythmically stimulate the brain at targeted frequencies. This produces changes in the brain at a molecular level, including reduction of key pathological proteins (Aβ and Tau) and improved neural connectivity. Our technology is protected by US patents No's: 11,730,975, 11,508,393, 8,930,292, 7,376,562 and 8,583,442 to Oscilloscape and International patents 2,529,369 (EU), 1,774,514 (EU), and 5,864,441 (Japan)

Exciting times ahead as I continue my journey with the incredible Vastly team, formerly known as Company.com! At Vastly, we're on a mission to redefine digital experience solutions, transforming the way organizations approach digital transformation. Our comprehensive suite of solutions empowers organizations (public and private sectors) to achieve their goals with reduced risk, minimized costs, and accelerated time to value. We specialize in end-to-end Enterprise Product Development Solutions, tackling the toughest challenges in today's dynamic business landscape. Our approach is marked by expert strategic advisory, seamless execution through our talented teams, and leveraging cutting-edge tools and technology. Follow my profile to stay updated on the latest trends, insights, and innovations driving digital experience solutions. Let's revolutionize together! #Vastly #DigitalTransformation #InnovationUnleashed #SOLaaS

Breezio is a Collaborative Research Platform that empowers researchers to tap into the collective intelligence of other researchers who are working on the same problems or projects.Breezio’s mission is to serve researchers by helping them accelerate discoveries by bringing experts together to solve some of the world biggest problems. Together we’ll achieve breakthrough collaborations!Our team has spent the last twenty years building communities and developing robust collaboration platforms for hundreds of thousands of people worldwide. We’ve learned a lot about how teams work best together and the tools necessary to break down the barriers so communities may collaborate effectively.

Collaborative Research Platform. Breezio’s mission is to serve researchers by helping you accelerate discoveries by bringing experts together to solve some of the world biggest problems. Together we’ll achieve breakthrough collaborations.Breezio helps research teams discover experts, publish articles, and collaborate around all forms of content through annotations, discussions, web-conferencing and much more, empowering your institute to accelerate the pace of innovation. Research teams may be as private or open as you like.

Oscillo Biosciences is a pre-commercial neurotechnology company developing medical devices and digital therapeutic platforms to treat serious neurodegenerative diseases like Alzheimer's Disease, Parkinson's, aphasia, dyslexia and others.Currently more than 6 million Americans suffer from dementia due to AD and the incidence is rising at an alarming rate. Alzheimer’s disease is the 5th leading cause of death among Americans age 65 and older. Among the top 10 causes of death, it is the only one for which there is no known cure. Alzheimer's disease requires extensive medical care, including diagnosis, treatment, and ongoing management. The cost of healthcare services for Alzheimer's patients is substantial, straining healthcare systems in large countries. For instance, in the United States, Alzheimer's disease is estimated to cost over $305 billion annually, making it the most expensive disease in the country (Alzheimer's Association, 2021). This cost includes Medicare and Medicaid expenses, hospital visits, and prescription medications. Our approach is predicated on the understanding that brain rhythms supporting memory and cognition are disrupted in people with Alzheimer’s disease. Recent studies have proven that stimulating brain waves at specific frequencies can bring about changes at the molecular level, diminishing brain plaques, untangling neural networks, and improving memory and cognition. Oscillo Biosciences has developed a non-invasive medical device and accompanying digital therapeutic platform that works by synchronizing specialized light pulses with familiar music to rhythmically stimulate the brain at targeted frequencies. This produces changes in the brain at a molecular level, including reduction of key pathological proteins (Aβ and Tau) and improved neural connectivity. Our technology is protected by US patents No's: 11,730,975, 11,508,393, 8,930,292, 7,376,562 and 8,583,442 to Oscilloscape, LLC; other US and International patents pending.

Founded in 2008, Company.com offers a unique Digital Experience Platform (DXP) that specializes in reducing time-to-value of integration, modernization and digital transformation initiatives. By building connected experiences that are technology-agnostic via micro-architecture and developer-friendly tools, the Company.com DXP allows businesses to deliver the value of a modern digital platform regardless of the challenges they face with their legacy infrastructure. Implementation use-cases include B2B ecommerce; customer and partner portals; intranets; headless APIs; and more. For more information on Company.com, please visit www.company.com or email media@company.com.

Internet social games and internet real money gaming platform (International only in countries that permit online gaming to licensed operators). GNS develops niche P-to-P games that are most popular in specific regions around the world. The first product developed and launched is the Phillipines nation game favorite Tong-its. Today, www.socialtongits.com is the largest social game platform for Tong-its in the world with over 700,000 registered users. GNS was granted a 15-year exclusive real money gaming license in 2013 through North Cagayan Gaming & Amusement Corporation, Phillipines for world wide player-to-player Tong-its. Real money play brand and website is: http://www.pinoytongits.com.

During my tenure as a director of iPayment, iPayment was acquired by PaySafe Group. Acquisition completed on 6/1/2018. Great outcome for the iPayment team and the shareholders of the company.

Onevest is the brand resulting from the merger between cofounderslab.com and Rock the Post. ONEVEST BRINGS TRANSPARENCY AND EASE TO STARTUP INVESTING.

Director and Investor

Sage Software plc is the owner of Sage Payment Solutions. Sage has approximately 15,000 world wide employees and the North American Region of Sage employees 5,500 as of 12/31/07. For more information regarding Sage - please see investor relations at www.sage.com